Status:
COMPLETED
Dental Pain (Following Third Molar Tooth Extraction) Study
Lead Sponsor:
GlaxoSmithKline
Conditions:
Dental Pain
Surgery, Dental
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
Detailed Description
A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg, and...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Scheduled for outpatient surgical removal of at least two third molar teeth.
- Exclusion criteria:
- Subjects who do not achieve moderate to severe pain.
- Subjects who do not use acceptable contraception.
- Additional medical criteria will be assessed by the investigator.
Exclusion
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00114049
Start Date
December 1 2004
End Date
April 1 2005
Last Update
January 19 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Austin, Texas, United States, 78703